GlassScriptPhysician profile
Awilda Nelida Belle
NPI 1164756490
$11,071.20
in general payments reported to CMS, 2019-2025
66 companies · $2,590 in 2025
The $2,590 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $627 · 2022: $2,254 · 2023: $2,687 · 2024: $2,912 · 2025: $2,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,825 · Long Term Medical Supply Or Device Loan: $1,049 · Education: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,825.36 |
| Long Term Medical Supply Or Device Loan | $1,049.07 |
| Education | $315.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,350.71 | 2022-2025 | Piqray, Kisqali |
| Gilead Sciences, INC. | $958.32 | 2022-2025 | Trodelvy |
| Janssen Biotech, INC. | $710.19 | 2021-2025 | Erleada, Rybrevant, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $617.17 | 2021-2025 | Opdivo, Opdualag |
| Abbvie INC. | $578.01 | 2021-2025 | |
| Pfizer INC. | $392.17 | 2022-2025 | |
| Incyte Corporation | $388.90 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Eisai INC. | $318.58 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $302.81 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $248.30 | 2022-2025 | |
| Lilly USA, LLC | $246.03 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Puma Biotechnology, INC. | $198.03 | 2021-2025 | |
| Daiichi Sankyo INC. | $192.78 | 2021-2025 | Enhertu |
| Glaxosmithkline, LLC. | $188.05 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Rigel Pharmaceuticals, INC. | $177.70 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $167.70 | 2022-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $157.07 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Amgen INC. | $152.29 | 2021-2023 | Lumakras, Nplate, Vectibix |
| Deciphera Pharmaceuticals INC. | $130.27 | 2021-2025 | Romvimza, Qinlock |
| Astellas Pharma US INC | $127.41 | 2021-2025 | Padcev, Xtandi |
| Regeneron Healthcare Solutions, INC. | $122.86 | 2022-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $120.62 | 2023-2025 | Fotivda |
| Adc Therapeutics America, INC. | $119.84 | 2023 | |
| Seagen INC. | $114.25 | 2021-2023 | Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $113.53 | 2022-2025 | Fruzaqla, Hyqvia, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $99.95 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $95.67 | 2021-2023 | Imbruvica |
| Mirati Therapeutics, INC. | $94.39 | 2024 | Krazati |
| Sanofi-Aventis U.S. LLC | $89.00 | 2022 | |
| Stemline Therapeutics INC. | $87.26 | 2023-2025 | Orserdu |
| Taiho Oncology, INC. | $86.34 | 2022-2025 | |
| Dendreon Pharmaceuticals LLC | $84.04 | 2023-2024 | Provenge |
| Celgene Corporation | $80.26 | 2023-2025 | Reblozyl |
| Array Biopharma INC | $74.71 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Beigene USA, INC. | $71.04 | 2024 | Brukinsa |
| Blueprint Medicines Corporation | $69.10 | 2023-2025 | Ayvakit |
| Jazz Pharmaceuticals INC. | $63.22 | 2022-2024 | |
| Pharmaessentia USA Corporation | $61.11 | 2023-2025 | Besremi |
| Kite Pharma, INC. | $59.21 | 2022-2023 | Yescarta |
| Legend Biotech USA INC. | $54.97 | 2024-2025 | Carvykti |
| Pharmacosmos Therapeutics INC. | $54.36 | 2023-2025 | Monoferric |
| Tersera Therapeutics LLC | $53.97 | 2025 | Zoladex |
| Novo Nordisk INC | $50.00 | 2021 | |
| Genentech USA, INC. | $49.28 | 2024-2025 | Phesgo, Tecentriq |
| Sobi, INC | $47.92 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $42.29 | 2023-2025 | Orgovyx |
| Genmab U.S., INC. | $39.88 | 2024-2025 | Epkinly |
| Karyopharm Therapeutics INC. | $36.48 | 2022-2024 | Xpovio |
| Myriad Genetic Laboratories, INC. | $32.45 | 2024 | Myrisk |
| Telix Pharmaceuticals | $24.57 | 2023 | Illuccix |
| Syndax Pharmaceuticals, INC. | $21.86 | 2025 | |
| Heron Therapeutics, INC. | $21.32 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.23 | 2024 | Somatuline Depot, Onivyde |
| Geron Corporation | $20.54 | 2024 | Rytelo |
| Csl Behring | $20.28 | 2022 | |
| Ge Healthcare | $20.07 | 2022 | |
| G1 Therapeutics, INC. | $19.14 | 2022 | |
| Progenics Pharmaceuticals, INC. | $16.72 | 2023 | Pylarify |
| Cti Biopharma Corp. | $15.06 | 2023 | Vonjo |
| Recordati_rare_diseases_inc. | $14.73 | 2024 | Sylvant |
| Emd Serono, INC. | $14.57 | 2025 | |
| Foundation Medicine, INC. | $14.52 | 2023 | |
| Shield Therapeutics INC | $14.21 | 2024 | |
| Beone Medicines USA, INC. | $14.12 | 2025 | Brukinsa |
| Medtronic, INC. | $14.05 | 2021 | |
| Acrotech Biopharma INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Awilda Belle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.